QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.oxaliplatinoxaliplatin and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.panobinostatziprasidone and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.perphenazineperphenazine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.pimavanserinpimavanserin and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug. Coadministration may increase the risk of QT prolongation and cardiac arrhythmia.pitolisantziprasidone and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.ponesimodponesimod, ziprasidone. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Consult cardiologist if considering treatment. Generally, should not be initiated in patients who are concurrently taking QT prolonging drugs with known arrhythmogenic properties, such as HR-lowering calcium channel blockers (eg, verapamil, diltiazem).pramipexoleziprasidone decreases effects of pramipexole by pharmacodynamic antagonism. Contraindicated.primaquineprimaquine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.prochlorperazineprochlorperazine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.promazinepromazine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.promethazinepromethazine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.protriptylineprotriptyline and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.ribociclibribociclib and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.ropiniroleziprasidone decreases effects of ropinirole by pharmacodynamic antagonism. Contraindicated.safinamideziprasidone decreases effects of safinamide by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Dopamine antagonists may decrease safinamide effects and exacerbate Parkinson disease symptoms.selinexorselinexor, ziprasidone. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.sevofluranesevoflurane and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.siponimodsiponimod and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.sodium oxybateziprasidone, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.solifenacinsolifenacin and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.sufentanil SLsufentanil SL, ziprasidone. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.sunitinibsunitinib and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.tacrolimustacrolimus and ziprasidone both increase QTc interval. Contraindicated.tetrabenazinetetrabenazine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.thioridazinethioridazine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.trazodonetrazodone and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.trifluoperazinetrifluoperazine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.trimipraminetrimipramine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.triptorelintriptorelin increases toxicity of ziprasidone by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.umeclidinium bromide/vilanterol inhaledziprasidone increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.vandetanibziprasidone, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.vemurafenibvemurafenib and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.vilanterol/fluticasone furoate inhaledziprasidone increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.vorinostatvorinostat and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.Monitor Closely (360)acarboseziprasidone, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.aclidiniumaclidinium decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.ziprasidone increases effects of aclidinium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.acrivastineacrivastine and ziprasidone both increase sedation. Use Caution/Monitor.albiglutideziprasidone, albiglutide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.albuterolziprasidone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.albuterol and ziprasidone both increase QTc interval. Use Caution/Monitor.alfentanilalfentanil and ziprasidone both increase sedation. Use Caution/Monitor.alfuzosinziprasidone and alfuzosin both increase QTc interval. Use Caution/Monitor.almotriptanalmotriptan, ziprasidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).alprazolamalprazolam and ziprasidone both increase sedation. Use Caution/Monitor.amifostineamifostine, ziprasidone. Either increases effects of the other by anti-hypertensive channel blocking. Use Caution/Monitor. Due to its alpha adrenergic antagonism, atypical antipsychotic agents has the potential to enhance the effect of certain antihypertensive agents. Monitor blood pressure and adjust dose accordingly.amitriptylineziprasidone and amitriptyline both increase sedation. Use Caution/Monitor.amobarbitalamobarbital and ziprasidone both increase sedation. Use Caution/Monitor.amoxapineziprasidone and amoxapine both increase sedation. Use Caution/Monitor.anticholinergic/sedative combosanticholinergic/sedative combos decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.anticholinergic/sedative combos decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.ziprasidone increases effects of anticholinergic/sedative combos by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.arformoterolziprasidone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.arformoterol and ziprasidone both increase QTc interval. Use Caution/Monitor.aripiprazolearipiprazole and ziprasidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.aripiprazole and ziprasidone both increase sedation. Use Caution/Monitor.armodafinilziprasidone increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.asenapineasenapine and ziprasidone both increase sedation. Use Caution/Monitor.asenapine transdermalasenapine transdermal and ziprasidone both increase sedation. Use Caution/Monitor.atogepantziprasidone will increase the level or effect of atogepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.atracuriumatracurium decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atracurium decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.ziprasidone increases effects of atracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropineatropine decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atropine decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.ziprasidone increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropine IV/IMziprasidone increases effects of atropine IV/IM by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropine IV/IM decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atropine IV/IM decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.avapritinibziprasidone will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.avapritinib and ziprasidone both increase sedation. Use Caution/Monitor.axitinibziprasidone increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.azelastineazelastine and ziprasidone both increase sedation. Use Caution/Monitor.azithromycinazithromycin and ziprasidone both increase QTc interval. Use Caution/Monitor.baclofenbaclofen and ziprasidone both increase sedation. Use Caution/Monitor.bedaquilineziprasidone and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closelybelladonna alkaloidsbelladonna alkaloids decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.belladonna alkaloids decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.ziprasidone increases effects of belladonna alkaloids by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.belladonna and opiumbelladonna and opium and ziprasidone both increase sedation. Use Caution/Monitor.belladonna and opium decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.belladonna and opium decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.ziprasidone increases effects of belladonna and opium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.benazeprilziprasidone, benazepril. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.benperidolbenperidol and ziprasidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.benperidol and ziprasidone both increase sedation. Use Caution/Monitor.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen and ziprasidone both increase sedation. Use Caution/Monitor.benzphetamineziprasidone increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.bosutinibbosutinib and ziprasidone both increase QTc interval. Use Caution/Monitor.brexanolonebrexanolone, ziprasidone. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazolebrexpiprazole and ziprasidone both increase sedation. Use Caution/Monitor.brimonidinebrimonidine and ziprasidone both increase sedation. Use Caution/Monitor.brivaracetambrivaracetam and ziprasidone both increase sedation. Use Caution/Monitor.brompheniraminebrompheniramine and ziprasidone both increase sedation. Use Caution/Monitor.buprenorphinebuprenorphine and ziprasidone both increase sedation. Use Caution/Monitor.buprenorphine buccalbuprenorphine buccal and ziprasidone both increase sedation. Use Caution/Monitor.buprenorphine subdermal implantbuprenorphine subdermal implant and ziprasidone both increase sedation. Use Caution/Monitor.buprenorphine transdermalbuprenorphine transdermal and ziprasidone both increase sedation. Use Caution/Monitor.buprenorphine, long-acting injectionziprasidone increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.buprenorphine, long-acting injection and ziprasidone both increase sedation. Use Caution/Monitor.butabarbitalbutabarbital and ziprasidone both increase sedation. Use Caution/Monitor.butalbitalbutalbital and ziprasidone both increase sedation. Use Caution/Monitor.butorphanolbutorphanol and ziprasidone both increase sedation. Use Caution/Monitor.caffeineziprasidone increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.capecitabinecapecitabine and ziprasidone both increase QTc interval. Use Caution/Monitor.carbamazepinecarbamazepine will decrease the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.carbinoxaminecarbinoxamine and ziprasidone both increase sedation. Use Caution/Monitor.carisoprodolcarisoprodol and ziprasidone both increase sedation. Use Caution/Monitor.cenobamatecenobamate, ziprasidone. Either increases effects of the other by sedation. Use Caution/Monitor.chloral hydratechloral hydrate and ziprasidone both increase sedation. Use Caution/Monitor.chlordiazepoxidechlordiazepoxide and ziprasidone both increase sedation. Use Caution/Monitor.chlorpheniraminechlorpheniramine and ziprasidone both increase sedation. Use Caution/Monitor.chlorpromazinechlorpromazine and ziprasidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and ziprasidone both increase sedation. Use Caution/Monitor.chlorpropamideziprasidone, chlorpropamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.chlorzoxazonechlorzoxazone and ziprasidone both increase sedation. Use Caution/Monitor.cimetidinecimetidine will increase the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cinnarizinecinnarizine and ziprasidone both increase sedation. Use Caution/Monitor.ciprofloxacinciprofloxacin and ziprasidone both increase QTc interval. Use Caution/Monitor. Ciprofloxacin elicits minimal effects on QT interval. Caution if used in combination with other drugs known to affect QT interval or in patients with other risk factors.cisatracuriumcisatracurium decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cisatracurium decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.ziprasidone increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.clarithromycinclarithromycin will increase the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.clemastineclemastine and ziprasidone both increase sedation. Use Caution/Monitor.clobazamziprasidone, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clomipramineziprasidone and clomipramine both increase sedation. Use Caution/Monitor.clonazepamclonazepam and ziprasidone both increase sedation. Use Caution/Monitor.clonidineclonidine, ziprasidone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.clorazepateclorazepate and ziprasidone both increase sedation. Use Caution/Monitor.clozapineclozapine and ziprasidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.clozapine and ziprasidone both increase sedation. Use Caution/Monitor.codeinecodeine and ziprasidone both increase sedation. Use Caution/Monitor.crizotinibcrizotinib and ziprasidone both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.cyclizinecyclizine and ziprasidone both increase sedation. Use Caution/Monitor.cyclizine decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cyclizine decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.ziprasidone increases effects of